Intervention not reported
Serious infections (requiring admission to hospital) ‐ not reported · patients with myelodysplastic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious bleeding (e.g. WHO/CTCAE grade 3 (or equivalent) or above ) ‐ not reported · patients with myelodysplastic syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Red blood cell transfusion requirements (units of red blood cells per patient per month) · patients with myelodysplastic syndrome
1 finding from 1 review
All‐cause mortality · participants with haematological malignancies
BMT showed no clear difference in mortality compared with PBSCT (high certainty).
1 finding from 1 review
Relapse, progression or death (calculated instead of PFS) · participants with haematological malignancies
BMT showed no clear difference in progress, relapse or death compared with PBSCT (moderate certainty).
1 finding from 1 review
Non relapse or transplant related mortality · participants with haematological malignancies
BMT showed no clear difference in non relapse or transplant related mortality compared with PBSCT (high certainty).
1 finding from 1 review
Chronic GVHD (extensive) · participants with haematological malignancies
BMT probably leads to lower extensive chronic GvHD compared with PBSCT (moderate certainty).
1 finding from 1 review
Acute GvHD III to IV · participants with haematological malignancies
BMT showed no clear difference in acute GvHD III to IV compared with PBSCT (moderate certainty).
1 finding from 1 review
Chronic GvHD overall · participants with haematological malignancies
BMT probably leads to lower chronic GvHD overall compared with PBSCT (moderate certainty).
1 finding from 1 review
Acute GVHD II to IV · participants with haematological malignancies
BMT showed no clear difference in acute GvHD II to IV compared with PBSCT (moderate certainty).
1 finding from 1 review
Intervention not reported
Mortality (0 to 26 months) · Haemopoietic stem cell donors
The intervention showed no clear difference in mortality (0 to 26 months) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events (day 7 to day 30 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review
Intervention not reported
Pain subsequent to donation ("after collection" ‐ day 30 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review
Intervention not reported
Psychological morbidity (immediately ‐ day 28 post‐donation) · Haemopoietic stem cell donors
1 finding from 1 review